Basic Research Support for the CCR

CCR的基础研究支持

• 批准号: 8350126
• 负责人: Robert Wiltrout
• 金额: $ 126.38万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8350126
• 关键词: Acquired Immunodeficiency Syndrome; Algorithms; Animal Technicians; Apoptotic; Area; Autoimmune Diseases; Basic Science; Biological Assay; Breast; Cancer Research Project; Cell Death; Cell Differentiation process; Cell Lineage; Cell Survival; Cell physiology; Cell surface; Chemistry; Clinical; Communicable Diseases; Comparative Carcinogenesis; Contrast Media; Dendritic Cells; Development; Disease; Drug Delivery Systems; Drug resistance; Effector Cell; Embryonic Development; Epigenetic Process; Event; Genetic; Glioma; Glycobiology; Growth; HIV; HLA Antigens; Hematopoiesis; Human Resources; Immune response; Immunobiology; Immunogenetics; Immunotherapy; Inflammation; Information Technology; Interleukin-7; Laboratories; Laboratory Animals; Laboratory Research; MHC Class II Genes; Malignant Neoplasms; Medical Imaging; Metabolism; Microarray Analysis; Mission; Molecular; Molecular Biology; Molecular Models; Molecular Target; Mus; NCI Center for Cancer Research; National Cancer Institute; Natural Products Chemistry; Neoplasm Metastasis; Nitric Oxide; Pathogenesis; Pathway interactions; Pattern; Play; Predisposition; Prevention therapy; Prostate; Protein Chemistry; Proteins; Qualifying; Reaction; Regulation; Renal Cell Carcinoma; Renal carcinoma; Research; Research Support; Resistance; Role; Scientist; Screening procedure; Signal Transduction; Stem cells; Stress; Structure; Susceptibility Gene; T-Lymphocyte and Natural Killer Cell; Technical Expertise; Urologic Oncology; Vaccines; anticancer research; base; cancer diagnosis; cancer genetics; cancer prevention; cancer stem cell; cancer therapy; carcinogenesis; cell growth; cell type; cellular imaging; cytokine; glycosyltransferase; metabolic abnormality assessment; molecular modeling; multidisciplinary; nanobiology; novel; programs; protein protein interaction; ras Proteins; self-renewal; stem cell biology; structural biology; tumor; tumorigenesis

The Basic Research Program (BRP provides scientific and technical expertise to the Center for Cancer Research (CCR) in areas ranging from cancer and human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), to the basic cellular processes underlying cancer, infectious diseases, and autoimmune disorders. Research topics supported by the BRP include: -Investigating ways in which novel, molecularly targeted cancer therapies can be used alone or in combination with immunotherapy in various tumor models (Molecular Immunotherapy Section, Cancer and Inflammation Program). -Understanding the genetic basis for resistance or susceptibility to disease conferred by human leukocyte antigen (HLA) class I and class II genes, which have a central role in the innate immune response (HLA Immunogenetics Section, Cancer and Inflammation Program). -Investigating the role of cytokines such as IL-7 in the development of T lymphocyte and natural killer (NK) cell lineages and their role in promoting cell survival, terminal differentiation, and apoptotic cell death (Immunological Cytokine Research Section, Cancer and Inflammation Program). -Examining the role of dendritic cells, other innate or adaptive effector cell types, and proinflammatory or immunoregulatory cytokines on carcinogenesis and cancer therapy (Cancer Immunobiology Section, Cancer and Inflammation Program). -Identifying and defining the molecular events that regulate lineage commitment and terminal differentiation of hemotopoietic stem cells (Hematopoiesis and Stem Cell Biology Section, Laboratory of Cancer Prevention). -Defining the cell surface markers, metastasis ability, and pathways for growth and self-renewal, of cancer stem cells from prostate, breast, glioma, and renal cell carcinomas (Cancer Stem Cell Section, Laboratory of Cancer Prevention). -Studying the role that epigenetic regulation plays in cellular differentiation, embryonic development, and tumorigenesis (Epigenetics Group, Laboratory of Cancer Prevention). -Understanding the structure and function of glycosyltransferases and developing novel glycosyltransferases for targeted drug delivery and contrast agents for medical imaging (Structural Glycobiology Section, CCR Nanobiology Program). -Developing highly efficient, state-of-the-art algorithms to discover the structural patterns of proteins and predict molecular associations (i.e., protein-protein interactions) in support of nanodesign for cancer diagnosis, therapy, and prevention (Computational Structural Biology Group, CCR Nanobiology Program). -Support in bioassay development and screening, natural products chemistry, protein chemistry, molecular biology, and high-content cellular imaging to facilitate multidisciplinary, molecular targets discovery research (Molecular Targets Laboratory). -Basic and applied chemistry support for studies characterizing the reactions of the bioregulatory agent nitric oxide (NO) with organic compounds (Chemistry Section, Laboratory of Comparative Carcinogenesis). -Microarray analysis aimed at determining the role of K-ras protein in controlling cell growth and differentiation (Cellular Pathogenesis Section, Laboratory of Comparative Carcinogenesis). -Studying the metabolic modulation of proliferative, apoptotic, and stress-related signaling in carcinogenesis and cancer susceptibility (Metabolism and Cancer Susceptibility Section, Laboratory of Comparative Carcinogenesis). -Discovery and characterization of renal carcinoma susceptibility genes (Urologic Oncology Research Group, Urologic Oncology Branch).

基础研究计划（BRP）为癌症研究中心（CCR）提供了科学和技术专业知识，从癌症和人类免疫缺陷病毒（HIV）/获得的免疫缺陷综合征（AIDS）（AIDS）（AIDS）到基本的细胞过程，到癌症的基本细胞过程到感染性疾病的基本细胞过程，包括研究型癌症。在各种肿瘤模型（分子免疫疗法部分，癌症和炎症计划）中，可以单独使用或与免疫疗法结合使用，以理解人白细胞抗原（HLA）II和类II类基因的遗传基础或疾病的易感性。 - 研究细胞因子（例如IL -7）在T淋巴细胞和天然杀伤（NK）细胞谱系发展中的作用及其在促进细胞存活，终末分化和凋亡细胞死亡（免疫学细胞因子研究部分，癌症和炎症计划）中的作用。 - 研究树突状细胞，其他先天或适应性效应细胞类型的作用，以及促炎或免疫调节性细胞因子在致癌和癌症治疗中的作用（癌症免疫生物学部分，癌症和炎症计划）。 - 识别并定义了调节血清干细胞谱系承诺和终末分化的分子事件（造血和干细胞生物学部分，预防癌症实验室）。 - 定义细胞表面标记，转移能力以及生长和自我更新的途径，来自前列腺，乳腺癌，神经胶质瘤和肾细胞癌（癌症干细胞部分，预防癌症预防实验室）的癌症干细胞。 - 研究表观遗传调节在细胞分化，胚胎发育和肿瘤发生（表观遗传学组，癌症预防实验室）中所发挥的作用。 - 理解糖基转移酶的结构和功能，并开发用于靶向药物递送的新型糖基转移酶和用于医学成像的对比剂（结构性糖生物学部分，CCR纳米生物学计划）。 - 开发高效，最先进的算法，以发现蛋白质的结构模式，并预测分子关联（即蛋白质 - 蛋白质相互作用），以支持纳米设计用于癌症诊断，治疗和预防（计算结构生物学组，CCR纳米生物学计划）。 - 在生物测定开发和筛选，天然产物化学，蛋白质化学，分子生物学和高含量细胞成像中的支持，以促进跨学科的分子靶标发现研究研究（分子靶标实验室）。 - 基本和应用化学支持，以表征生物调节剂一氧化氮（NO）与有机化合物的反应的研究（化学部分，比较癌变实验室）。 - 微阵列分析旨在确定K-RAS蛋白在控制细胞生长和分化中的作用（细胞发病机理部分，比较癌变实验室）。 - 研究癌变和癌症易感性（代谢和癌症易感性部分，比较癌变实验室）的增生，凋亡和与压力相关的信号的代谢调节。 - 肾癌易感基因（泌尿科肿瘤研究小组，泌尿外科肿瘤学分支）的发现和表征。